PharmaPROP.BXL
The computed 12-month bankruptcy probability of PharmaPROP.BXL is 9.3% (elevated). The 2024 annual accounts show negative equity (€-1k) and a net result of €-2k. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-1k |
| Net result | €-2k |
| Active | 3 yrs |
| Locations | 1 |
Mixed profile: strong on profitability, weaker on health.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €46k |
| Net profit | €-2k |
| Cash flow | €29k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €883k |
| Equity | €-1k |
| Debt | €884k |
| of which ≤ 1y | €236k |
| of which > 1y | €642k |
| Working capital | €-205k |
| Employees (FTE) | 0.0 |
| 2024 | |
|---|---|
| Current ratio | 0.13 |
| Quick ratio | 0.13 |
| Working capital ratio | -23.2% |
| Solvency | -0.1% |
| Debt / equity | -760.27 |
| Long-term debt ratio | -552.13 |
| Interest coverage | 2.71 |
| Gross margin | - |
| Net margin | - |
| ROA | -0.2% |
| ROE | 186.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €883k |
| Fixed assets | 21/28 | €852k |
| Tangible fixed assets | 22/27 | €852k |
| Current assets | 29/58 | €31k |
| Amounts receivable within one year | 40/41 | €24k |
| Cash & bank | 54/58 | €8k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €883k |
| Equity | 10/15 | €-1k |
| Contributions / capital | 10/11 | €1k |
| Accumulated profits (losses) | 14 | €-2k |
| Amounts payable | 17/49 | €884k |
| Amounts payable after one year | 17 | €642k |
| Amounts payable within one year | 42/48 | €236k |
| Trade debts payable within one year | 44 | €406 |
| Income statement | ||
| Gross operating margin | 9900 | €50k |
| Operating result | 9901 | €15k |
| Financial charges | 65 | €17k |
| Result before taxes | 9903 | €-2k |
| Net result for the period | 9904 | €-2k |
| Result to be appropriated | 9905 | €-2k |
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 08-08-2023 |
| Status | Active |
| Postal code | 1000 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21803C0405/00H000 | Brussels | 211 m² | 1 · 172 m² | 22.4 m · 6 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
13-04-2026 Act object · General meeting · Permanent representative · Officer resignation
- Filing: 2026-04-03 · PharmaPROP.BXL
- Publication: 2026-04-13 · PharmaPROP.BXL
- Act object: Constatation changement représentant permanent · PharmaPROP.BXL
- General meeting: 2026-02-13 · PharmaPROP.BXL
- Permanent representative: role: représentant permanent, context: représentation de la société-administrateur PharmaBXL au sein de PharmaPROP.BXL, start_date: 2025-12-12 · Georges DE FEU
- Officer resignation: role: représentant permanent, context: remplacement par Georges DE FEU, end_date: 2025-12-12 · Olivier OLBRECHTS
- Approval: meeting_date: 2026-02-13, decision_date: 2025-12-12, approving_body: organe d'administration de la SRL PharmaBXL, approved_by_meeting: assemblée générale spéciale de PharmaPROP.BXL · PharmaPROP.BXL
Technical details
{
"facts": [
{
"type": "filing",
"quote": "D\u00E9pos\u00E9 / Re\u00E7u le U 3 AVR. 2026",
"value": "2026-04-03",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 13/04/2026",
"value": "2026-04-13",
"object": null,
"subject": "e1"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Constatation changement repr\u00E9sentant permanent",
"value": "Constatation changement repr\u00E9sentant permanent",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "Extrait du proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale sp\u00E9ciale tenue le 13/02/2026",
"value": "2026-02-13",
"object": null,
"subject": "e1"
},
{
"type": "permanent_representative",
"quote": "L\u0027assembl\u00E9e constate que la soci\u00E9t\u00E9-administrateur, SRL \u00AB PharmaBXL \u003E (num\u00E9ro d\u0027entreprise 0795.508.480), est repr\u00E9sent\u00E9e par Monsieur Georges DE FEU en qualit\u00E9 de repr\u00E9sentant permanent, \u00E0 compter du 12/12/2025",
"value": {
"role": "repr\u00E9sentant permanent",
"context": "repr\u00E9sentation de la soci\u00E9t\u00E9-administrateur PharmaBXL au sein de PharmaPROP.BXL",
"start_date": "2025-12-12"
},
"object": "e2",
"subject": "e3"
},
{
"type": "officer_resignation",
"quote": "et non plus par Monsieur Olivier OLBRECHTS.",
"value": {
"role": "repr\u00E9sentant permanent",
"context": "remplacement par Georges DE FEU",
"end_date": "2025-12-12"
},
"object": "e2",
"subject": "e4"
},
{
"type": "approval",
"quote": "L\u0027assembl\u00E9e prend acte de la d\u00E9cision prise le 12/12/2025 par l\u0027organe d\u0027administration de la SRL \u003C\u003C PharmaBXL \u00BB (num\u00E9ro d\u0027entreprise 0795.508.480), qui est soci\u00E9t\u00E9-administrateur de notre soci\u00E9t\u00E9.",
"value": {
"meeting_date": "2026-02-13",
"decision_date": "2025-12-12",
"approving_body": "organe d\u0027administration de la SRL PharmaBXL",
"approved_by_meeting": "assembl\u00E9e g\u00E9n\u00E9rale sp\u00E9ciale de PharmaPROP.BXL"
},
"object": "e2",
"subject": "e1"
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 1529,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0804.643.803",
"kind": "company",
"name": "PharmaPROP.BXL",
"attrs": {
"address": "Avenue Albert 154, 1190 Forest",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e2",
"kbo": "0795.508.480",
"kind": "company",
"name": "PharmaBXL",
"attrs": {
"role": "soci\u00E9t\u00E9-administrateur",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Georges DE FEU",
"attrs": {
"role": "repr\u00E9sentant permanent"
}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "Olivier OLBRECHTS",
"attrs": {
"role": "ancien repr\u00E9sentant permanent"
}
}
]
}10-08-2023 Incorporation of a new SRL
Technical details
{
"kind": "oprichting",
"seat": "1190 Forest, Avenue Albert 154",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": null,
"name": "PHARMABXL"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "A",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PHARMABXL",
"contribution_type": "cash",
"amount_paid_in_eur": 900,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 900000,
"amount_subscribed_eur": 900,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "FILIP GILIAS"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "FILIP GILIAS",
"contribution_type": "cash",
"amount_paid_in_eur": 122.96,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 12296,
"amount_subscribed_eur": 122.96,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "REMEDIA"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "REMEDIA",
"contribution_type": "cash",
"amount_paid_in_eur": 134.89,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 13489,
"amount_subscribed_eur": 134.89,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "PHARMALEGAL"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PHARMALEGAL",
"contribution_type": "cash",
"amount_paid_in_eur": 496.23,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 49623,
"amount_subscribed_eur": 496.23,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "O2C"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "O2C",
"contribution_type": "cash",
"amount_paid_in_eur": 245.92,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 24592,
"amount_subscribed_eur": 245.92,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1000,
"subject_company": {
"kbo": "0804.643.803",
"name_full": "PharmaPROP.BXL",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2023-08-07",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PharmaPROP.BXL |